What is Ottimo Pharma?
Ottimo Pharma is dedicated to advancing the treatment of solid tumors through the development of innovative cancer therapies. The company's lead asset, Jankistomig, is a novel PD1/VEGFR2 bifunctional antibody. This IgG therapy is designed as a dual pathway, biparatopic single-agent treatment, aiming to simultaneously target immune checkpoint inhibition and angiogenesis. By pursuing this dual-pathway approach, Ottimo Pharma seeks to broaden the therapeutic window, enhance patient outcomes in cancer treatment, and alleviate the overall healthcare burden associated with the disease.
How much funding has Ottimo Pharma raised?
Ottimo Pharma has raised a total of $140M across 1 funding round:
Other Financing Round
$140M
Other Financing Round (2024): $140M with participation from Samsara BioCapital, OrbiMed, and Avoro Capital
Key Investors in Ottimo Pharma
Samsara BioCapital
Samsara BioCapital is a venture capital firm focused on creating transformative therapeutics. They partner with scientists and drug developers to support next-generation therapeutic breakthroughs in the biopharmaceutical sector.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They support companies at various stages of development with a comprehensive understanding of healthcare innovation.
Avoro Capital
Avoro Capital Advisors is a global investment firm specializing in the biotechnology and life sciences sectors. They focus on supporting emerging companies by identifying unique investment opportunities and providing financial and intellectual support to address unmet medical needs.
What's next for Ottimo Pharma?
With the recent major strategic investment, Ottimo Pharma is poised to accelerate the development of its lead asset, Jankistomig. This enterprise-level funding suggests the company is moving towards later-stage clinical trials and potential commercialization efforts. The backing from prominent investors in the life sciences sector indicates strong confidence in Ottimo Pharma's scientific approach and its potential to disrupt the oncology market. Future strategic moves will likely focus on advancing Jankistomig through regulatory pathways and expanding its pipeline of innovative cancer therapies.
See full Ottimo Pharma company page
